NCT07915219
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Trial sites expanded: 383 → 394 locations
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Participants with bronchiectasis who completed parent trials AIRTIVITY® (1397-0014) or CLAIRLEAF® (1397-0017) and did not prematurely discontinue the trial drug.
Drugs: verducatib
Sites
394 sites in 41 countries
United States 51, China 48, Japan 35, Germany 31, Spain 21, United Kingdom 21, South Korea 16, Italy 15, Bulgaria 13, Argentina 11, France 11, Brazil 7, Latvia 7, Mexico 7, Poland 7, Portugal 7, Canada 6, Denmark 6, Israel 6, Netherlands 6, Malaysia 5, Philippines 5, Belgium 4, Finland 4, Romania 4, Singapore 4, Taiwan 4, Thailand 4, Hungary 3, Lithuania 3, Sweden 3, Austria 2, Chile 2, Czechia 2, Hong Kong 2, Ireland 2, Kazakhstan 2, Slovakia 2, Switzerland 2, Turkey (Türkiye) 2, South Africa 1